ArticleJournal of molecular histology2016
Downregulation of the long noncoding RNA TUG1 inhibits the proliferation, migration, invasion and promotes apoptosis of renal cell carcinoma.
Article in Journal of molecular histology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- TUG1, SPRY4-IT1, and HULC as valuable prognostic biomarkers of survival in cancer: A PRISMA-compliant meta-analysis.Medicine · 2017Pooled it
- Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications.Oncotarget · 2017Pooled it
- lncRNA TUG1 and kidney diseases.BMC nephrology · 2025Review
- Long non-coding RNABrain communications · 2024Article
- Association of lncRNA and transcriptome intersections with response to targeted therapy in metastatic renal cell carcinoma.Oncology letters · 2023Article
- LncRNA TUG1 aggravates cardiomyocyte apoptosis and myocardial ischemia/reperfusion injury.Histology and histopathology · 2021Article
- Long non-coding RNA TUG1 promotes proliferation and migration in PDGF-BB-stimulated HASMCs by regulating miR-216a-3p/SMURF2 axis.BMC molecular and cell biology · 2021Article
- Long non-coding RNA TUG1/microRNA-187-3p/TESC axis modulates progression of pituitary adenoma via regulating the NF-κB signaling pathway.Cell death & disease · 2021Article
- Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer.OncoTargets and therapy · 2021Review
- LINC00671 inhibits renal cell cancer progression via regulating miR-221-5p/SOCS1 axis.American journal of translational research · 2021Article
- Article
- LOC101060264 Silencing Suppresses Invasion and Metastasis of Human Colon Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- LINC00689 promotes prostate cancer progression via regulating miR-496/CTNNB1 to activate Wnt pathway.Cancer cell international · 2020Article
- Long non-coding RNA TUG1 knockdown hinders the tumorigenesis of multiple myeloma by regulating the microRNA-34a-5p/NOTCH1 signaling pathway.Open life sciences · 2020Article
- Long Non-Coding RNA TUG1 Promotes Cell Proliferation and Inhibits Cell Apoptosis, Autophagy in Clear Cell Renal Cell Carcinoma via MiR-31-5p/FLOT1 Axis.OncoTargets and therapy · 2020Article
- Molecular mechanisms of TUG1 in the proliferation, apoptosis, migration and invasion of cancer cells.Oncology letters · 2019Review
- LncRNA TUG1 promotes the development of osteosarcoma through RUNX2.Experimental and therapeutic medicine · 2019Article
- Article
- Long noncoding RNA ATB participates in the development of renal cell carcinoma by downregulating p53 via binding to DNMT1.Journal of cellular physiology · 2019Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs, a newly discovered category of noncoding genes, play a leading role in various biological processes, including tumorigenesis. In our study, we aimed to examine the TUG1 expression, and explore the influence of TUG1 silencing on cell proliferation and apoptosis in renal cell carcinoma (RCC) cell lines. The TUG1 expression level was detected using quantitative real-time PCR reverse transcription-polymerase chain reaction in 40 paired clear cell renal cell carcinoma (ccRCC) and adjacent paired normal tissues, as well as four RCC cell lines and one normal human proximal tubule epithelial cell line HK-2. Small interfering RNA was applied to suppress the TUG1 expression in RCC cell lines (A489 and A704). In vitro assays were conducted to further deliberate its potential functions in RCC progression. The relative TUG1 expression was significantly higher in ccRCC tissues compared to the adjacent normal renal tissues. In addition, higher TUG1 expression was equally detected in RCC cell lines (particularly in A498 and A704) compared to HK-2. The ccRCC specimens with higher TUG1 expression had a higher Fuhrman grade and larger tumor size than those with lower TUG1 expression. In vitro assays results suggested that knockdown of TUG1 suppressed RCC cells migration, invasion and proliferation, while the apoptosis process was activated. Our results indicate that TUG1 is identified as a novel oncogene in the morbid state of RCC, which potentially acts as a therapeutic target/biomarker in RCC. The graphic abstract of the present work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.